uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis
Microbiology and Tumour Biology Center, Karolinska Institute, S-171 77 Solna, Sweden.
2004 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 48, no 4, 1289-1294 p.Article in journal (Refereed) Published
Abstract [en]

Rifampin is a major drug used in the treatment of tuberculosisinfections, and increasing rifampin resistance represents aworldwide clinical problem. Resistance to rifampin is causedby mutations in the rpoB gene, encoding the ß-subunitof RNA polymerase. We examined the effect of three differentrpoB mutations on the fitness of Mycobacterium tuberculosis.Rifampin-resistant mutants were isolated from a virulent clinicalisolate of M. tuberculosis (strain Harlingen) in vitro at amutation frequency of 2.3 x 10-8. Mutations in the rpoB genewere identified, and the growth rates of three defined mutantswere measured by competition with the susceptible parent strainin laboratory medium and by single cultures in a macrophagecell line and in laboratory medium. All of the mutants showeda decreased growth rate in the three assays. The relative fitnessof the mutants varied between 0.29 and 0.96 (that of the susceptiblestrain was set to 1.0) depending on the specific mutant andassay system. Unexpectedly, the relative fitness ranking ofthe mutants differed between the different assays. In conclusion,rifampin resistance is associated with a cost that is conditional.

Place, publisher, year, edition, pages
2004. Vol. 48, no 4, 1289-1294 p.
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:uu:diva-68008PubMedID: 15047531OAI: oai:DiVA.org:uu-68008DiVA: diva2:95919
Available from: 2005-02-09 Created: 2005-02-09 Last updated: 2017-11-21Bibliographically approved

Open Access in DiVA

No full text

Other links

PubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15047531&dopt=Citation

Authority records BETA

Andersson, Dan I

Search in DiVA

By author/editor
Andersson, Dan I
In the same journal
Antimicrobial Agents and Chemotherapy
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 592 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf